DSHEA 1994

Before 1994, the regulatory status of dietary supplements was ambiguous and contested. FDA had repeatedly attempted to regulate high-potency vitamins, herbal products, and amino acids as either food additives (requiring premarket approval) or unapproved new drugs (when bearing health-related claims). The industry, supported by consumer-advocacy groups, mobilised an unprecedented lobbying campaign, and Congress responded with the Dietary Supplement Health and Education Act of 1994, signed into law on 25 October 1994. DSHEA explicitly carved out 'dietary supplements' as a distinct subcategory of food — not drugs, not food additives — and set the regulatory framework that still governs the category today.

DSHEA added §201(ff) to the FD&C Act, defining a 'dietary supplement' as a product (other than tobacco) intended to supplement the diet that bears or contains one or more of the following dietary ingredients:

• A vitamin;
• A mineral;
• An herb or other botanical;
• An amino acid;
• A dietary substance for use by man to supplement the diet by increasing the total dietary intake;
• A concentrate, metabolite, constituent, extract, or combination of any of the above.

The product must also be: intended for ingestion in tablet, capsule, powder, softgel, gelcap, or liquid form (and not represented as a conventional food); labelled as a dietary supplement; and not represented for use as a sole item of a meal or of the diet. The 'intended for ingestion' clause is why topical creams, transdermal patches, and inhaled products cannot be lawfully marketed as dietary supplements under DSHEA.

The most consequential single change DSHEA made: it shifted the burden of proof for safety from the manufacturer (premarket) to FDA (post-market). For a conventional food additive, the manufacturer must prove the additive is safe before it can be marketed. For a drug, the manufacturer must prove safety AND efficacy through NDAs. For a dietary supplement under DSHEA, the manufacturer must only ensure the supplement is not adulterated — and FDA must prove, post-market, that a supplement presents a 'significant or unreasonable risk' before it can be removed from the market.

The single exception: new dietary ingredients (introduced after 15 October 1994) require a 75-day premarket safety notification under §413 — but FDA does not 'approve' the NDI; it can only object. This burden allocation is why FDA must build extensive post-market evidence to remove products like ephedra (banned in 2004 after years of adverse-event accumulation), DMAA (action in 2013), and BMPEA (action in 2014).

DSHEA drew a permanent line at 15 October 1994. Any dietary ingredient marketed in the US in a dietary supplement before that date is a 'grandfathered' (or 'old') dietary ingredient and requires no premarket notification. Any dietary ingredient introduced after that date is a New Dietary Ingredient (NDI) and requires a §413 premarket safety notification 75 days before marketing — unless it has been 'present in the food supply as an article used for food in a form in which the food has not been chemically altered' (a narrow exemption almost nobody qualifies for cleanly). FDA has no comprehensive list of grandfathered ingredients; industry trade associations (AHPA, CRN) maintain partial lists, and the burden of demonstrating pre-1994 marketing falls on the manufacturer making the claim.

DSHEA established three on-label claim categories for dietary supplements:

The structure/function claim (the most-used of the three) requires the mandatory FDA disclaimer ('This statement has not been evaluated by the FDA…'), a 30-day post-market notification, and competent and reliable scientific substantiation on file. Disease claims remain forbidden — they trigger the drug-claim threshold of §201(g) and convert the supplement into an unapproved new drug.

DSHEA §9 (codified at FD&C Act §402(g)) gave FDA explicit authority to issue current Good Manufacturing Practice regulations specifically for dietary supplements — modelled on but separate from the drug cGMP at 21 CFR Part 211 and the food cGMP at 21 CFR Part 110 (now 117). FDA took 13 years to finalise the rule: 21 CFR Part 111 was published in June 2007 (72 FR 34751) and phased in by company size through June 2010. Part 111 is the heart of every modern supplement compliance program, and the rule against which FDA's annual hundreds of Warning Letters to supplement manufacturers are written.

• DSHEA did NOT require adverse-event reporting. That gap closed in 2006 with DSNDCPA (Public Law 109-462), which added mandatory 15-business-day serious-AE reporting under §761.
• DSHEA did NOT require facility registration. That gap closed in 2002 with the Bioterrorism Preparedness Act, then strengthened in 2011 with FSMA — supplement facilities must register and renew biennially under §415.
• DSHEA did NOT include premarket safety review (except NDIs). FDA still cannot demand a safety dossier on a new finished supplement before it is marketed.
• DSHEA did NOT create a Mandatory Product Listing — Congress has repeatedly proposed one (most recently the DSLA Act of 2022/2023, which would require manufacturers to list every marketed supplement with FDA), but as of 2026 no such law has passed.
• DSHEA did NOT include manufacturer disclosure of clinical evidence for claims. Substantiation must be 'on file' but is not publicly accessible.

DSHEA's burden-of-proof framework enabled the US dietary-supplement industry to grow from approximately $4 billion in annual revenue in 1994 to over $60 billion today. The trade-off has been recurring safety controversies (ephedra, kava, DMAA, BMPEA, kratom), persistent adulteration of botanical products with undisclosed pharmaceutical actives (the 'spiking' problem most acute in weight-loss, sexual-enhancement, and sports-performance categories), and chronic friction between FDA and industry over the boundary between structure/function and disease claims. The 2022 Government Accountability Office report and the 2023 Senate HELP Committee hearings represent the most recent serious attempts to modernise DSHEA, but the statute's central architecture remains intact.

• Industry profile 'dietary_supplements' unlocks the full DSHEA-aware feature set.
• Material catalogue stores ndi_status (grandfathered | ndi_notified | exempt_food_supply | unknown).
• Claim register stores claim text + disclaimer + 30-day notification ID + substantiation file links.
• MMR + BPR + 111.75 identity test + 111.70(e) finished-product spec workflows enforced.
• DSNDCPA AE reporting workflow ships in the same module (15-business-day MedWatch 3500A).
• FDA-inspection mode renders a DSHEA + Part 111 compliance pack from the regulated-reports bucket.